Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Avantor Inc

Healthcare US AVTR

9.35USD
-0.23(2.40%)

Last update at 2026-06-22T20:00:00Z

Day Range

9.359.62
LowHigh

52 Week Range

7.2615.93
LowHigh

Fundamentals

  • Previous Close 9.58
  • Market Cap5817.94M
  • Volume7390595
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA975.50M
  • Revenue TTM6552.20M
  • Revenue Per Share TTM9.63
  • Gross Profit TTM 2139.40M
  • Diluted EPS TTM-0.78

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -441.30000M 853.90M 410.50M 851.10M 753.00M
Minority interest - - - - -
Net income -530.20000M 711.50M 321.10M 686.50M 572.60M
Selling general administrative 1595.50M 1641.10M 1506.60M 1472.60M 1530.50M
Selling and marketing expenses - - - - -
Gross profit 2139.40M 2279.30M 2363.80M 2602.80M 2502.70M
Reconciled depreciation 410.20M 405.50M 402.30M 405.50M 379.20M
Ebit -271.50000M 1072.70M 695.30M 1130.20M 972.20M
Ebitda 138.70M 1478.20M 1097.60M 1534.90M 1362.00M
Depreciation and amortization 410.20M 405.50M 402.30M 404.70M 389.80M
Non operating income net other - - - -13.30000M -1.80000M
Operating income -246.20000M 1084.80M 696.40M 1130.20M 972.20M
Other operating expenses 6798.40M 5698.80M 6270.80M 6382.20M 6413.90M
Interest expense 169.80M 218.80M 284.80M 265.80M 217.40M
Tax provision 88.90M 142.40M 89.40M 164.60M 180.40M
Interest income - - - - -
Net interest income -169.80000M -218.80000M -284.80000M -265.80000M -217.40000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 88.90M 142.40M 89.40M 164.60M 180.40M
Total revenue 6552.20M 6783.60M 6967.20M 7512.40M 7386.10M
Total operating expenses 2385.60M 1194.50M 1667.40M 1472.60M 1530.50M
Cost of revenue 4412.80M 4504.30M 4603.40M 4909.60M 4883.40M
Total other income expense net -195.10000M -230.90000M -285.90000M -279.10000M -219.20000M
Discontinued operations - - - - -
Net income from continuing ops -530.20000M 711.50M 321.10M 686.50M 572.60M
Net income applicable to common shares - - - 662.30M 508.00M
Preferred stock and other adjustments - - - 24.20M 64.60M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 11794.70M 12114.50M 12972.70M 13464.30M 13897.20M
Intangible assets 3193.80M 3359.90M 3775.30M 4133.30M 5140.30M
Earning assets - - - - -
Other current assets 193.00M 118.70M 143.70M 153.10M 81.40M
Total liab 6229.70M 6157.80M 7720.10M 8608.90M 9700.20M
Total stockholder equity 5565.00M 5956.70M 5252.60M 4855.40M 4197.00M
Deferred long term liab - - - 731.40M 913.00M
Other current liab 606.40M 523.60M 594.50M -195.00000M 401.00M
Common stock 3984.80M 3937.70M 3830.10M 3785.30M 2752.60M
Capital stock 3984.80M 3937.70M 3830.10M 3785.30M 3756.30M
Retained earnings 1672.80M 2203.00M 1491.50M 1170.40M 483.90M
Other liab - - - 940.20M 1271.40M
Good will 4986.90M 5539.20M 5716.70M 5652.60M 5341.10M
Other assets - 0.30M - 174.80M 233.10M
Cash 365.40M 261.90M 262.90M 372.90M 301.70M
Cash and equivalents - - - - -
Total current liabilities 1378.90M 2007.50M 1480.30M 1658.80M 1450.80M
Current deferred revenue - - 183.30M 731.40M 249.50M
Net debt 3580.90M 3793.90M 5273.70M 5914.60M 6721.50M
Short term debt 30.80M 821.10M 259.90M 364.20M 45.20M
Short long term debt 30.80M 821.10M 259.90M 364.20M 45.20M
Short long term debt total 3946.30M 4055.80M 5536.60M 6287.50M 7023.20M
Other stockholder equity -75.70000M 2203.00M -0.00000M -100.30000M 1003.70M
Property plant equipment - - - 727.00M 705.50M
Total current assets 2451.20M 2146.60M 2384.90M 2657.90M 2477.20M
Long term investments - - - - -
Net tangible assets - - - -4930.50000M -7288.10000M
Short term investments - - 16.60M - -
Net receivables 1074.60M 1034.50M 1150.20M 1218.40M 1222.10M
Long term debt 3915.50M 3234.70M 5276.70M 5923.30M 6978.00M
Inventory 818.20M 731.50M 828.10M 913.50M 872.00M
Accounts payable 741.70M 662.80M 625.90M 758.20M 755.10M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -16.90000M -184.00000M -69.00000M -100.30000M -43.20000M
Additional paid in capital - - - - -
Common stock total equity - - - 3785.30M 2752.60M
Preferred stock total equity - - - - 1003.70M
Retained earnings total equity - - - 1170.40M 483.90M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 396.00M 360.40M 187.50M 293.50M 233.10M
Deferred long term asset charges - - - - -
Non current assets total 9343.50M 9967.60M 10587.80M 10806.40M 11420.00M
Capital lease obligations - - - - -
Long term debt total - - - 5923.30M 6978.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 438.90M -126.80000M -109.60000M -4121.70000M
Change to liabilities - - - 15.70M 64.90M
Total cashflows from investing activities -130.50000M 438.90M -143.70000M -109.60000M -4121.70000M
Net borrowings -318.70000M -1341.80000M -846.00000M -620.40000M 2300.70M
Total cash from financing activities -409.40000M -1281.20000M -843.70000M -648.70000M 3219.20M
Change to operating activities - - - -179.20000M 62.20M
Net income -530.20000M 711.50M 321.10M 686.50M 572.60M
Change in cash 103.60M -23.00000M -109.20000M 69.80M 37.90M
Begin period cash flow 264.70M 287.70M 396.90M 327.10M 289.20M
End period cash flow 368.30M 264.70M 287.70M 396.90M 327.10M
Total cash from operating activities 623.80M 840.80M 870.00M 843.60M 953.60M
Issuance of capital stock - - 0.00000M 0.00000M 967.00M
Depreciation 410.20M 405.50M 402.30M 405.50M 379.20M
Other cashflows from investing activities -1.70000M 587.70M 2.70M -18.70000M 3.50M
Dividends paid - 0.00000M 18.30M -32.40000M -64.60000M
Change to inventory -109.40000M -18.50000M 30.30M -112.50000M -129.80000M
Change to account receivables 13.60M 45.90M 77.00M -45.20000M -111.80000M
Sale purchase of stock -80.70000M -8.60000M -13.70000M -13.20000M -25.80000M
Other cashflows from financing activities -15.10000M 69.20M 16.00M 343.90M 2876.50M
Change to netincome - - - -7.80000M 100.00M
Capital expenditures 128.80M 148.80M 146.40M 133.40M 111.10M
Change receivables - - - -45.20000M -111.80000M
Cash flows other operating - - - -114.30000M 101.80M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 85.30M 51.10M
Change in working capital -198.90000M 47.70M 16.60M -321.30000M -114.50000M
Stock based compensation 46.40M 46.80M 40.50M 45.80M 50.70M
Other non cash items 888.60M -323.80000M 261.90M 96.20M 83.30M
Free cash flow 495.00M 692.00M 723.60M 710.20M 842.50M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AVTR
Avantor Inc		 -0.23 2.40% 9.35 - 8.30 0.89 1.03 1.42 67.25
ISRG
Intuitive Surgical Inc		 -3.83 0.94% 402.95 73.05 61.73 19.15 10.25 18.41 59.92
ESLOF
EssilorLuxottica Société anonyme		 -13.86 6.73% 192.00 44.84 27.62 4.07 2.49 3.71 16.04
ESLOY
Essilor International SA		 -5.56 5.46% 96.36 41.68 27.25 3.94 2.45 3.71 16.04
BDX
Becton Dickinson and Company		 -3.27 2.27% 140.71 25.56 12.48 2.59 1.76 2.89 12.55

Reports Covered

Stock Research & News

View All

Profile

Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, compound management, cleanroom control, monitoring, maintenance, and sanitization services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.

Avantor Inc

Radnor Corporate Center, Radnor, PA, United States, 19087

Key Executives

Name Title Year Born
Mr. Michael Stubblefield Pres, CEO & Director 1973
Mr. Thomas A. Szlosek Exec. VP & CFO 1964
Dr. Gerard Brophy Ph.D. Exec. VP of Biopharma Production 1966
Mr. Frederic Vanderhaegen Exec. VP of Europe 1967
Ms. Sheri Lewis Exec. VP of Global Supply Chain 1966
Mr. Steven W. Eck Sr. VP, Corp. Controller & Chief Accounting Officer 1977
Mr. Michael Wondrasch Exec. VP & Chief Information Officer 1969
Mr. Tommy J. Thomas CPA VP of Investor Relations NA
Mr. Justin M. Miller Esq. Exec. VP, Gen. Counsel & Sec. 1967
Ms. Allison K. Hosak Sr. VP of Global Communications & Brand NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.